Loading...
Immunotherapies for Infectious Diseases Congress 2017

December 11 - 12 LYON - Congress Center

News Twitter

Programme

schedule & speakers

Your company develops immunotherapies for infectious diseases and you want to present your scientific work at the I4ID 2017 congress? Check-out our sponsors & partners page to discover our sponsored presentation opportunities.

Day 1

Monday 11 December 2017

8h30

Registration & welcome coffee

9h00

Welcome address & Opening Lecture

9h30

Keynote Lecture

Markus Maeurer

Markus Maeurer
Head of the Division Therapeutic Immunology at LabMed
Karolinska Institute

10h00

Plenary session 1 : Immunotherapies against viral infections

Overview on mAbs for HIV, RSV, HBV, CMV

Hugo Mouquet

Hugo Mouquet
Head of Lab, Humoral Response to Pathogens Lab & INSERM U1222
Pasteur Institute, France
Decoding Human B-cell Responses to Viruses: Learning from Monoclonal Antibodies

Pascal Poignard

Pascal Poignard
Head of HIV and persistant viruses group
IBS, France
HIV: title to be determined

11h00

Coffee break - networking - stand / Partnering (B2B) / Poster Session

11h30

Plenary session 1 (2nd part) : Immunotherapies against viral infections

Overview on mAbs for HIV, RSV, HBV, CMV

Geneviève Inchauspé

Geneviève Inchauspé
Senior Director, Head of the Department of Infectious Diseases
Transgene, France
Therapeutic vaccination in chronic infectious diseases: the place of vectored vaccines

JoAnn Suzich

JoAnn Suzich
VP of Infectious Disease and Vaccines Research
MedImmune, USA
A vaccine surrogate for the prevention of RSV disease

12h30

Lunch - networking - stand / Partnering (B2B) / Poster Session

14h00

Plenary session 2 : Immunotherapies as alternative treatment to antibiotics

New approaches to fight against S.aureus, P. aeruginosa, E.coli…

Bruno François

Bruno François
Specialist in Intensive Care medicine and Anesthesiology
Centre Hospitalier Universitaire de Limoges, France
Antibody-based therapy against Staphylococcus aureus infections

Hasan Jafri

Hasan Jafri
Senior Director, Clinical Research and Development, Infectious Disease & Vaccines
MedImmune, USA
P. aeruginosa: Title to be determined

Eszter Nagy

Eszter Nagy
Co-founder & Chief Scientific Officer
Arsanis, Austria
Monoclonal antibody therapeutics to fight MDR Gram negative pathogens

16h00

Coffee break - networking - stand / Partnering (B2B) / Poster Session

16h30

Pitch Session

Scientific and technological innovation in diagnostics and immunotherapies for infectious diseases

19h00

End of day one

20h00

Gala Evening

Day 2

Tuesday 12 December 2017

8h00

Welcome coffee

8h15

Keynote Lecture : Regulatory overview

9h00

Plenary session 3 : Immunotherapies against emergent or re-emergent and bioterrorism agents

Immunotherapies developed against Ebola, hemorrhagic fevers, Zika…

Bertrand Lépine

Bertrand Lépine
Chief Executive Officer
Fab'Entech, France
Ebola: title to be determined

Jonathan Abraham

Jonathan Abraham
Member of the Faculty, Department of Microbiology and Immunobiology
Harvard Medical School, USA
Neutralization of New World hemorrhagic fevers arenaviruses by receptor-binding site targeting antibodies

10h00

Coffee break - networking - stand / Partnering (B2B) / Poster Session

10h30

Plenary session 3 (2nd part) : Immunotherapies against emergent or re-emergent and bioterrorism agents

Immunotherapies developed against Ebola, hemorrhagic fevers, Zika…

Davide Corti

Davide Corti
Chief Scientific Officer and Vice-President
Humabs, Switzerland
Zika : title to be determined

Berend Jan Bosch

Berend Jan Bosch
Assistant Professor
Utrecht University - The Netherlands
Antigenic structure of the MERS-coronavirus spike protein characterized by monoclonal antibodies

Marie Mandron

Marie Mandron
Anti CHIKV mAb Project Leader
Sanofi
Recombinant Fully-Human mAbs for the treatment of Chikungunya Virus Disease

12h30

Lunch - networking - stand / Partnering (B2B) / Poster Session

14h00

Plenary Session 4 : Next generation immunotherapies against infectious diseases

Alternative mAb formats and host-directed immunotherapies

Tony De Fougerolles

Tony De Fougerolles
Chief Scientific Officer
Ablynx, The Netherlands
title to be determined

Arne Skerra

Arne Skerra
Full Professor and Chair of Biological Chemistry
Technical University of Munich, Germany
Anticalins as a novel class of clinical stage alternative immunotherapies: from oncology to infectious diseases

Pierre-Olivier Vidalain

Pierre-Olivier Vidalain
Research Director, CNRS
Paris Descartes University, France
Looking for modulators of the innate immune response: a chemo-biological approach

16h00

Cross-talk : Challenges for access to immunotherapies in emerging countries.

Marc Bonneville

Marc Bonneville
Scientific & Medical Affairs Director
Institut Mérieux

Martin Friede

Martin Friede
Coordinator of Initiative for Vaccine Research
WHO

Sébastien Quesney

Sébastien Quesney
Director Access to Diagnosis/Neglected Diseases
Fondation Mérieux

Stéphane Debuire

Stéphane Debuire
Head of Commercial Operations Access to Medecine
Sanofi

Menzo Havenga

Menzo Havenga
Chief Executive Officer
Batavia Biosciences

Partnering (B2B) / Poster Session

17h00

Closing remark

17h30

End of Symposium

Gala Evening – Cocktail Diner Cruise

Enjoy a Cocktail Diner Cruise in the l’OFFICIEL Yacht while networking.
Departure at the Cité Internationale docks for a 2 hours cruise in the Rhône river.
A unique experience to discover Lyon by night in the best Yachting’s spirit.

l’OFFICIEL Yachtl’OFFICIEL Yachtl’OFFICIEL Yachtl’OFFICIEL Yacht

Attention – limited number of places available